Head-to-Head Efficacy and Safety Results in First-Line CLL

  • July 23, 2015

Designed to determine the superior anti-CD20 regimen for typical* patients1-4

CLL-11 is a Phase III trial that evaluated GAZYVA + Clb against rituximab + Clb to establish a first-line treatment for typical CLL patients, based on age and coexisting medical conditions1-4

  • The safety and efficacy of GAZYVA + Clb was evaluated in a Stage I comparison of Arm 1 (Clb alone) vs Arm 2 (GAZYVA + Clb) in 356 patients, and a Stage II comparison of Arm 2 (GAZYVA + Clb) vs Arm 3 (rituximab + Clb) in 663 patients1
  • In the CLL patient population, the median age at diagnosis was 71 years, and 89% had at least one coexisting medical condition3,4
  • CLL-11 enrolled patients with a median age of 73 years (range: 39-90), and 100% had at least one coexisting medical condition or reduced renal function1,2

*Based on age and coexisting medical conditions.

For more information visit Start with GAZYVA® (obinutuzumab)

© 2021 FLASCO | Premium Website Design by The HDG